A draft of the FDA user fee reauthorization legislation circulating in the House includes several modifications to agency operations that would alter the tone of its interaction with industry.
Under the discussion draft, FDA’s mission statement would be changed to focus on a regulatory system that: advances...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?